Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG
Abstract Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half‐life, lecanemab administered as a bi‐monthly infusion (typically...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.52227 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249851658305536 |
|---|---|
| author | Jean‐Pierre Bellier Andrea M. Román Viera Caitlyn Christiano Juliana A. U. Anzai Stephanie Moreno Emily C. Campbell Lucas Godwin Amy Li Alan Y. Chen Sarah M. Alam Adriana Saba Han Bin Yoo Hyun‐Sik Yang Jasmeer P. Chhatwal Dennis J. Selkoe Lei Liu |
| author_facet | Jean‐Pierre Bellier Andrea M. Román Viera Caitlyn Christiano Juliana A. U. Anzai Stephanie Moreno Emily C. Campbell Lucas Godwin Amy Li Alan Y. Chen Sarah M. Alam Adriana Saba Han Bin Yoo Hyun‐Sik Yang Jasmeer P. Chhatwal Dennis J. Selkoe Lei Liu |
| author_sort | Jean‐Pierre Bellier |
| collection | DOAJ |
| description | Abstract Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half‐life, lecanemab administered as a bi‐monthly infusion (typically 10 mg/kg) has a relatively brief half‐life. Interaction with abundant plasma proteins binder in the bloodstream can affect pharmacokinetics of drugs, including their half‐life. In this study, we investigated potential plasma protein binding (PPB) interaction to lecanemab using lecanemab biosimilar. Methods Lecanemab biosimilar used in this study was based on publicly available sequences. ELISA and western blotting were used to assess lecanemab biosimilar immunoreactivity in the fractions of human plasma obtained through size exclusion chromatography. The binding of lecanemab biosimilar to candidate plasma binders was confirmed by western blotting, ELISA, and surface plasmon resonance analysis. Results Using a combination of equilibrium dialysis, ELISA, and western blotting in human plasma, we first describe the presence of likely PPB partners to lecanemab biosimilar and then identify fibrinogen as one of them. Utilizing surface plasmon resonance, we confirmed that lecanemab biosimilar does bind to fibrinogen, although with lower affinity than to monomeric amyloid beta. Interpretation In the context of lecanemab therapy, these results imply that fibrinogen levels could impact the levels of free antibodies in the bloodstream and that fibrinogen might serve as a reservoir for lecanemab. More broadly, these results indicate that PPB may be an important consideration when clinically utilizing therapeutic antibodies in neurodegenerative disease. |
| format | Article |
| id | doaj-art-a2937031280e43858e2d3edef81ce057 |
| institution | OA Journals |
| issn | 2328-9503 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj-art-a2937031280e43858e2d3edef81ce0572025-08-20T01:58:23ZengWileyAnnals of Clinical and Translational Neurology2328-95032024-12-0111123192320410.1002/acn3.52227Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgGJean‐Pierre Bellier0Andrea M. Román Viera1Caitlyn Christiano2Juliana A. U. Anzai3Stephanie Moreno4Emily C. Campbell5Lucas Godwin6Amy Li7Alan Y. Chen8Sarah M. Alam9Adriana Saba10Han Bin Yoo11Hyun‐Sik Yang12Jasmeer P. Chhatwal13Dennis J. Selkoe14Lei Liu15Department of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartment of Neurology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USAAbstract Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half‐life, lecanemab administered as a bi‐monthly infusion (typically 10 mg/kg) has a relatively brief half‐life. Interaction with abundant plasma proteins binder in the bloodstream can affect pharmacokinetics of drugs, including their half‐life. In this study, we investigated potential plasma protein binding (PPB) interaction to lecanemab using lecanemab biosimilar. Methods Lecanemab biosimilar used in this study was based on publicly available sequences. ELISA and western blotting were used to assess lecanemab biosimilar immunoreactivity in the fractions of human plasma obtained through size exclusion chromatography. The binding of lecanemab biosimilar to candidate plasma binders was confirmed by western blotting, ELISA, and surface plasmon resonance analysis. Results Using a combination of equilibrium dialysis, ELISA, and western blotting in human plasma, we first describe the presence of likely PPB partners to lecanemab biosimilar and then identify fibrinogen as one of them. Utilizing surface plasmon resonance, we confirmed that lecanemab biosimilar does bind to fibrinogen, although with lower affinity than to monomeric amyloid beta. Interpretation In the context of lecanemab therapy, these results imply that fibrinogen levels could impact the levels of free antibodies in the bloodstream and that fibrinogen might serve as a reservoir for lecanemab. More broadly, these results indicate that PPB may be an important consideration when clinically utilizing therapeutic antibodies in neurodegenerative disease.https://doi.org/10.1002/acn3.52227 |
| spellingShingle | Jean‐Pierre Bellier Andrea M. Román Viera Caitlyn Christiano Juliana A. U. Anzai Stephanie Moreno Emily C. Campbell Lucas Godwin Amy Li Alan Y. Chen Sarah M. Alam Adriana Saba Han Bin Yoo Hyun‐Sik Yang Jasmeer P. Chhatwal Dennis J. Selkoe Lei Liu Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG Annals of Clinical and Translational Neurology |
| title | Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG |
| title_full | Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG |
| title_fullStr | Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG |
| title_full_unstemmed | Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG |
| title_short | Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG |
| title_sort | identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar igg |
| url | https://doi.org/10.1002/acn3.52227 |
| work_keys_str_mv | AT jeanpierrebellier identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT andreamromanviera identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT caitlynchristiano identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT julianaauanzai identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT stephaniemoreno identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT emilyccampbell identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT lucasgodwin identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT amyli identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT alanychen identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT sarahmalam identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT adrianasaba identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT hanbinyoo identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT hyunsikyang identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT jasmeerpchhatwal identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT dennisjselkoe identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg AT leiliu identificationoffibrinogenasaplasmaproteinbindingpartnerforlecanemabbiosimilarigg |